FFA
PTCT icon

Farther Finance Advisors’s PTC Therapeutics PTCT Stock Holding History

Farther Finance Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$32.1K Sell
496
-197
-28% -$14.3K ﹤0.01% 3776
2026
Q2 		$56.5K Buy
693
+142
+26% +$10.3K ﹤0.01% 3155
2026
Q1 		$37.9K Buy
551
+200
+57% +$14.2K ﹤0.01% 3200
2025
Q4 		$26.7K Buy
351
+128
+57% +$9.3K ﹤0.01% 3242
2025
Q3 		$13.7K Sell
223
-2,411
-92% -$126K ﹤0.01% 3270
2025
Q2 		$129K Buy
2,634
+2,622
+21,850% +$124K ﹤0.01% 1630
2025
Q1 		$559 Hold
12
– – ﹤0.01% 3754
2024
Q4 		$542 Sell
12
-3
-20% -$128 ﹤0.01% 3428
2024
Q3 		$557 Buy
15
+10
+200% +$335 ﹤0.01% 3400
2024
Q2 		$156 Buy
5
+3
+150% +$97 ﹤0.01% 3532
2024
Q1 		$57 Hold
2
– – ﹤0.01% 3455
2023
Q4 		$55 Sell
2
-1
-33% -$23 ﹤0.01% 3369
2023
Q3 		$67 Hold
3
– – ﹤0.01% 2560
2023
Q2 		$122 Hold
3
– – ﹤0.01% 2416
2023
Q1 		$145 Hold
3
– – ﹤0.01% 2253
2022
Q4 		$115 Buy
+3
New +$125 ﹤0.01% 2124

Other funds holding PTCT

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return
SA
Sacks & Associates Warren, New Jersey $143M AUM 17.48% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Farther Finance Advisors's PTCT Position: Q3 2026 in Review

Farther Finance Advisors reduced its PTC Therapeutics (PTCT) stake by 28% in Q3 2026, selling an estimated $14.3K and leaving 496 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3776.

Farther Finance Advisors first reported a position in PTCT in Q4 2022 and has held it in 16 quarters since. The position peaked at $129K in Q2 2025. 8 funds tracked by Wall St. Rank hold PTCT as of Q3 2026.

  • Farther Finance Advisors held 496 shares of PTC Therapeutics worth $32.1K as of Q3 2026.
  • Farther Finance Advisors sold 197 PTC Therapeutics shares in Q3 2026, an estimated $14.3K.
  • PTC Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3776 holding.
  • Farther Finance Advisors first reported a position in PTC Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • Farther Finance Advisors's PTC Therapeutics position peaked at $129K in Q2 2025.
  • 8 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.